

1 **Microbiome-based biomarkers to guide personalized microbiome-**  
2 **based therapies for Parkinson’s disease.**

3

4 Haydeh Payami\* <sup>1,2</sup>, Timothy R Sampson <sup>2,3</sup>, Charles F Murchison <sup>1,2,4</sup>

5

6 <sup>1</sup> Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA

7 <sup>2</sup> Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase,  
8 MD, 20815, USA

9 <sup>3</sup> Department of Cell Biology, Emory University, Atlanta, GA, 30329, USA

10 <sup>4</sup> Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, 35233,  
11 USA

12

13 **\*Senior and Corresponding author:**

14 Haydeh Payami, PhD

15 University of Alabama at Birmingham, Room 429, Civitan International Research Center, 1719  
16 6th Ave S, Birmingham, AL 35233

17 Phone: 205-994-1909

18 Email: haydehpayami@uabmc.edu

19

20 **Running title:** Microbiome-based biomarkers

21 **Word count:** Abstract 125. Introduction 448. Method 995. Results 610. Discussion 867.

22 32 references. 2 Tables. 3 Figures.

## 23 **Abstract**

24

25 We address an unmet challenge in Parkinson's disease: the lack of biomarkers to identify the  
26 right patients for the right therapy, which is a main reason clinical trials for disease modifying  
27 treatments have all failed. We present the gut microbiome as a target for treatment and  
28 introduce microbiome-based biomarkers to guide personalized treatments. We show that not all  
29 persons with PD have a dysbiotic microbiome, and not all dysbiotic PD microbiomes have the  
30 same features. We have developed an intuitive and easily modifiable method to identify the  
31 optimal candidates for microbiome-based clinical trials, and subsequently, for treatments that  
32 are personalized for each individual's dysbiotic features. We demonstrate the method for PD.  
33 The concept, and the method, is generalizable for any disease with a microbiome component.

34

## 35 **Introduction**

36

37 Parkinson's disease (PD) is the fastest growing neurologic disease in the world <sup>1</sup>. PD is a  
38 progressively debilitating disease <sup>2</sup>. The earliest manifestations are often constipation, sleep  
39 disorder, and hyposmia, leading to the cardinal movement disorders, and as disease  
40 progresses, most patients develop psychosis and dementia. Treatments are symptomatic.  
41 There have been many clinical trials for disease modifying treatment aimed at stopping disease  
42 progression, and all have failed (clinicaltrials.gov). PD is a highly heterogenous disease. One  
43 treatment will not work for all patients. Biomarkers to guide selection of the right patients for the  
44 right drug has been a high-priority, unmet need.

45

46 It has long been known that constipation, inflammation in the gut, and permeable gut membrane  
47 are common in PD and precede motor signs <sup>2</sup>. Recent studies suggest some cases of PD start  
48 in the gut and spread to the brain, and in rodent models, PD pathologies are observed to spread  
49 from gut to brain <sup>3-7</sup>. The gut origin raised the possibility that the gut microbiome could be  
50 involved in the brain-gut-axis pathology of PD. A healthy gut microbiome controls metabolism of  
51 drugs, toxicants and food, synthesis of vitamins and neurotransmitters, keeps the lining of the  
52 gut intact, protects against pathogens, maintains the proper functioning of the immune and  
53 nervous systems, and modulates brain-gut communication <sup>8</sup>.

54

55 It is becoming increasingly clear that the gut microbiome is severely dysbiotic in PD<sup>9-11</sup>, with  
56 features that could directly affect initiation and progression of PD. Dysbiotic features of PD  
57 microbiome are relevant to multiple PD mechanisms<sup>9</sup>, including increased abundance of  
58 pathogens and immunogens, decreased production of neuroactive molecules (dopamine,  
59 serotonin, glutamate and GABA), reduced capacity to degrade plant-based fiber which leads to  
60 short chain fatty acids deficiency, increased inflammation and compromised gut barrier, and  
61 elevated *E. coli* and curli. Curli is a bacterial amyloid produced by *E. coli* which, in mice, induces  
62 alpha-synuclein aggregation, the hallmark of PD pathology<sup>12,13</sup>. Data from genetic and toxicant-  
63 induced models of PD also suggest gut microbiome can trigger or contribute to various PD  
64 pathologies and the manifestation of motor and non-motor phenotypes<sup>14-17</sup>, and that altering the  
65 microbiome via fecal microbiome transplantation (FMT)<sup>18,19</sup>, antibiotics treatments<sup>20-23</sup>, or high  
66 fiber diet<sup>24</sup>, each to some extent can reduce alpha-synuclein pathology, inflammation, and motor  
67 and non-motor dysfunction.

68  
69 The gut microbiome is an emerging target for PD therapies<sup>25,26</sup>. Results of early clinical trials  
70 with fiber supplementation<sup>27</sup> and FMT<sup>28-31</sup> are promising. Next-generation targeted therapeutics  
71 are forthcoming. Here, we show that not all PD patients have a dysbiotic microbiome and not all  
72 dysbiotic microbiomes have the same features. We introduce microbiome-based biomarkers to  
73 guide patient selection for clinical trials, and upon success, as companion diagnostic for  
74 personalized treatment.

75

## 76 **The Method**

77

### 78 **Overview**

79

80 The overview of the method is shown in **Figure 1**. The concept and method are generalizable to  
81 any disorder with a microbiome component, here, we focus on PD. The method requires a  
82 metagenomics reference dataset from older adults without PD. Non-PD individuals should be  
83 from the same population as the patients to be studied or treated (such reference datasets will  
84 soon be available for several populations). We select features of interest as potential targets for  
85 treatment. Features can be a single gene or metabolite, a species, a cluster of related species,  
86 or multiple polymicrobial clusters that are being targeted for treatment. We then calculate the  
87 mean relative abundance and confidence intervals (CI) of the features in the metagenomics  
88 dataset of older adults without PD. We have now created the reference dataset. We define

89 dysbiosis by setting thresholds for relative abundances in reference dataset (e.g., outside 95%  
90 CI). Patients can now be screened for dysbiotic features, which entails obtaining a stool sample,  
91 metagenomic sequencing and comparing the relative abundance of the features in the patient to  
92 the reference dataset and the thresholds that define dysbiosis.

93

#### 94 **Foundation of the method**

95

96 We previously conducted a large-scale high-resolution metagenomic analysis, where we  
97 mapped the dysbiotic features of PD microbiome<sup>9</sup>. Results were published and all data and  
98 protocols are open access without restriction (see Data Availability). The dataset is composed of  
99 deep-shotgun next-generation metagenome sequences of microbial DNA, extracted from stool  
100 samples of 490 individuals with PD and 234 neurologically healthy controls (NHC). We  
101 conducted a metagenome-wide association study (MWAS) and identified species, genes and  
102 pathways that are depleted or overly abundant in PD. We also conducted correlations network  
103 analysis (using SparCC) and identified polymicrobial clusters of species whose abundances  
104 grow or shrink together<sup>9</sup>. The visual of PD microbiome network and its clusters resembles and  
105 thus is called Fireworks (**Figure 2**).

106

#### 107 **The concept**

108

109 The published study<sup>9</sup> was microbiome-centric, i.e., we identified dysbiotic features in  
110 aggregates of patients as compared to NHC. We now turn the approach around and make it  
111 individual-centric, i.e., what does the microbiome in a given patient look like? Is the microbiome  
112 dysbiotic in every PD patient? Are all dysbiotic features present together, or are some features  
113 present in a subset of patients, and if so, what percentage of patients has a given dysbiotic  
114 feature? The answers to these questions are fundamental to any microbiome-based  
115 therapeutic. To answer these questions, we had to (a) select features of interest that could  
116 potentially be a target of treatment and (b) create an operational definition of dysbiosis. The  
117 concept is generalizable, and the method, both feature selection and definition of dysbiosis, can  
118 be modified to accommodate study design.

119

#### 120 **Features of PD gut microbiome**

121

122 For feature selection, we used the data reported in Wallen et al<sup>9</sup>. We selected species that were  
123 significantly associated with PD (i.e., their abundance was elevated or reduced in PD)<sup>9</sup>, plus the  
124 cluster of rare opportunistic pathogens, which were too rare to be tested individually, but form a  
125 polymicrobial cluster that was shown in two independent datasets to be elevated in PD<sup>9,32</sup>. We  
126 grouped the selected PD-associated species into six features based on the correlation in their  
127 abundances ( $|r|>0.2$ ,  $P<0.05$ ) and taxonomic relatedness (members of same genus). The six  
128 dysbiotic features (**Table 1, Figure 2**) are as follows: (1) the cluster of opportunistic pathogens  
129 (elevated in PD), (2) species of *Bifidobacteria* (elevated in PD), (3) species of *Lactobacillus*  
130 (elevated in PD), (4) *Streptococcus* and *Actinomyces* species that are elevated in PD, (5) *E. coli*  
131 and *Klebsiella* species that are elevated in PD, and (6) fiber-degrading bacteria (reduced in PD).  
132 There is more to the dysbiosis of PD gut than these six features<sup>9</sup>. The features can be  
133 redefined to accommodate the aims of the investigation. Here, we strived for a balance between  
134 minimizing complexity while capturing the most robust and biologically relevant features. The  
135 aim was to demonstrate the method behind microbiome-based biomarkers.

136

### 137 **Definition of dysbiotic and non-dysbiotic**

138

139 We needed a working definition of dysbiotic. First step is to optimize patient selection for clinical  
140 trials. To that end, we set high thresholds for defining dysbiosis in order to maximize the odds  
141 that the patient being enrolled is an optimal candidate. These thresholds can be changed to  
142 accommodate study design, or relaxed when a drug is approved, and the biomarkers become  
143 companion diagnostics for personalized treatment.

144

145 For each feature, and per person, we calculated total relative abundance of each feature by  
146 summing the relative abundances of the species within it. We then calculated the mean relative  
147 abundance and its 95% CI in NHC (reference dataset). Next, we turned to individual-level PD  
148 data. Considering each feature separately, we called a PD person's metagenome dysbiotic if the  
149 relative abundance of the feature was outside the 95% CI of NHC. For features that are  
150 elevated in PD in aggregate data, a PD individual's gut was called dysbiotic if the relative  
151 abundance of the feature in that person was greater than the upper bound of 95% CI of NHC.  
152 For the feature that is reduced in PD, a PD individual's microbiome was called dysbiotic if the  
153 relative abundance of the feature in that person was less than the lower bound of 95% CI of  
154 NHC (**Table 2**).

155

156 A key question was whether all individuals with PD have a dysbiotic gut microbiome. To answer  
157 this question, we needed an operational definition of non-dysbiotic. We defined non-dysbiotic  
158 per feature as being well within the norm of NHC range, i.e., below the mean of NHC if the  
159 feature is elevated in PD, and above the mean if a feature is reduced in PD. When considering  
160 all six features, a PD person was designated as not having a dysbiotic microbiome only if their  
161 relative abundance for the five elevated features were all at or below the mean of NHC, and  
162 their relative abundance for reduced fiber degrading feature was at or greater than the mean in  
163 NHC.

164

## 165 **Results**

166

167 **Not all PD metagenomes are dysbiotic, and not all dysbiotic microbiomes have the same**  
168 **features.**

169

170 Among 490 individuals with PD studied, 392 (80%) had at least one dysbiotic feature (**Figure**  
171 **3a**). 98 (20%) did not have any dysbiotic feature defined as being outside the 95% CI of NHC.  
172 Using the more cautious definition of non-dysbiotic, i.e. elevated features being at or below the  
173 NHC mean and reduced features at or above the NHC mean, 76 (16%) of PD microbiomes  
174 were not dysbiotic. The patients without a dysbiotic microbiome can be identified and excluded  
175 from microbiome-based therapeutics; doing so will boost power and odds of success of clinical  
176 trials, and in clinical setting, will spare these patients unnecessary trial and error in finding the  
177 right treatment.

178

179 Severe reduction in fiber-degrading bacteria was seen in 333 of 490 of PD patients (68%)  
180 (**Figure 3a**). Among the 333 low fiber-degraders, only 96 had no other dysbiotic features  
181 (**Figure 3b**), hence 71%  $(=(333-96)/333)$  of patients with low fiber-degraders had high levels of  
182 at least one other dysbiotic feature. Thus, while deficiency of fiber degraders is very common,  
183 only 20%  $(=96/490)$  of PD patients had low fiber-degraders as their sole feature. This suggests  
184 that while fiber treatment would be beneficial for majority of patients, a subset would stand to  
185 benefit the most from fiber, while others may need treatment for their other dysbiotic features as  
186 well.

187

188 Features that are elevated in PD were found in subsets of patients: high levels of opportunistic  
189 pathogens was detected in 66 (13%) of the 490 PD, *Bifidobacterium* in 161 (33%), *Lactobacillus*

190 in 103 (21%), *Streptococcus* and *Actinomyces* in 94 (19%), and *E. coli* and *Klebsiella* in 86  
191 (18%). To demonstrate utility of the biomarker, consider *E. coli* which has been linked to  
192 pathobiology of PD. *E. coli* encodes curli, an amyloid that induces alpha-synuclein aggregation  
193 in mice<sup>12,13</sup>. Alpha-synuclein aggregation is a pathogenic hallmark of PD. Moreover, *E. coli* and  
194 genes that encode and regulate curli production are elevated in PD gut<sup>9</sup>. Should a drug be  
195 developed against *E. coli* or curli, it will likely have a far better odds of success in clinical trial if  
196 patients were chosen from the 18% that have high levels of *E. coli* and curli.

197  
198 There is some overlap across the groups shown in **Figure 3a**, because these features are not  
199 mutually exclusive. For example, as shown in **Figure 3b**, among the 66 patients with high  
200 opportunistic pathogens, 33 (50%) also had high *Bifidobacteria*, 15 (23%) had high  
201 *Lactobacillus*, 18 (27%) had high *Streptococcus* and *Actinomyces*, 13 (20%) had *E. coli* and  
202 *Klebsiella*, and 57 (86%) had low fiber degraders. These data suggest that at the present time,  
203 with fiber and FMT being the only microbiome-based treatments, the most rational option for  
204 treating the patients who have a severely dysbiotic microbiome is cleansing the microbiome with  
205 antibiotics followed by FMT, excluding those without dysbiosis and those with only low fiber-  
206 degraders. We are not advocating for FMT or any treatment modality per se, rather, pointing out  
207 the utility of biomarkers in designing a study as well as choosing the patients to study and treat.

208

### 209 **Application of the biomarker tool**

210

211 Defining the features of interest and setting abundance thresholds to define dysbiotic/non-  
212 dysbiotic in a healthy population will constitute the reference dataset for this biomarker tool. To  
213 determine the composition of the metagenome of a patient will entail obtaining a stool sample,  
214 DNA extraction, sequencing, bioinformatic processing and taxonomic assignment of sequences,  
215 and calculating relative abundances of the microbial features. The patient's relative abundances  
216 for the features of interest are then compared to the reference dataset to determine if they are  
217 dysbiotic (**Figure 1**).

218

### 219 **Discussion**

220

221 Here, we introduced a microbiome-based biomarker tool to guide patient selection for clinical  
222 trials and to serve as companion diagnostic for personalized treatments. With this tool, we can  
223 “see” if and what is dysbiotic in an individual and act accordingly. The method is applicable for

224 any patient at any stage of disease. The tool can be easily modified (by redefining features and  
225 adjusting thresholds) as the field advances, and to meet varying needs of different studies.  
226 Here, we demonstrated the development and the potential utility of the tool for identifying  
227 subtypes of PD based on their microbiome features. The concept is generalizable to any  
228 disease with a microbiome component.

229  
230 Treating a dysbiotic microbiome can potentially be disease modifying, which has been an  
231 elusive goal in PD field. Functional inference of human data and experiments in mice indicate  
232 dysbiotic features of PD microbiome contribute to several disease mechanisms, including alpha-  
233 synuclein aggregation which is at the core of PD pathology, disrupted neuro-signaling, and  
234 inflammation<sup>9,13,14</sup>. It is therefore reasonable to work towards microbiome-based therapies that  
235 could halt disease progression. As we learn which features are causal and which result from  
236 disease (an active area of research), microbiome-based biomarkers will be useful for identifying  
237 pathogenic dysbiosis early to prevent disease before onset.

238  
239 Microbiome-based treatments under consideration for PD include prebiotics (e.g., fiber  
240 supplements), probiotics (beneficial bacteria packaged and marketed direct to consumer), FMT,  
241 and next generation therapeutics that are targeted to a specific feature (e.g., small molecules,  
242 phage, CRSPR-Cas9). The microbiome-based biomarkers described here can serve as  
243 companion diagnostic for all treatment modalities. Take fiber supplementation for example,  
244 which is safe and likely beneficial for everyone. We show here that indeed, the majority of PD  
245 patients have severely depleted levels of fiber-degrading bacteria. Increasing fiber intake is  
246 effectively feeding these bacteria and causing them to grow and multiply, and it has shown  
247 promise in an early clinical trial with newly diagnosed PD patients<sup>27</sup>. The value of coupling  
248 biomarkers with fiber treatment is in identifying patients who, in addition to being low on fiber-  
249 degraders, have elevated levels of harmful pathogenic bacteria, which is an important  
250 consideration both for patient selections for clinical trials and for treating the individuals. As for  
251 probiotics on the market, most are composed of “beneficial” species of *Bifidobacteria* and/or  
252 *Lactobacillus*, which ironically, are highly elevated in PD. The value of the biomarker in this case  
253 is to avoid supplementation that is counter indicated. FMT is showing promise for PD<sup>28</sup>, but it  
254 carries risks concerning safety and compatibility of donor sample with host environment. Using  
255 biomarkers, unnecessary FMT can be avoided, sparing the patients who do not have a dysbiotic  
256 microbiome and those whose only problem is low fiber-degraders. Targeted treatments could  
257 replace the need for FMT, and they too would benefit from a companion diagnostic. For



258 example, for a treatment targeted to abolish the opportunistic pathogens, the biomarker can  
259 identify the 13% of patients who would be the best candidates.

260  
261 Currently, we do not know if alleviating one dysbiotic feature would restore homeostasis to the  
262 rest of the microbiome, and what that central feature might be. Consumption of fiber is the  
263 safest and simplest treatment. In a clinical trial performed on 20 newly diagnosed PD patients,  
264 treatment with fiber increased the abundance of fiber-degrading bacteria and production of short  
265 chain fatty acids and resulted in shifts in the microbiome community<sup>27</sup>. Fiber-degrading species  
266 are in the center of the Firework with tight positive and negative correlations to several PD-  
267 associated species (**Figure 2**). It is therefore plausible that fiber treatment, aimed to increase  
268 the abundance of fiber-degrading bacteria, may restore equilibrium to PD-associated species  
269 that map to the center of Firework and are either positively or negatively correlated with fiber-  
270 degraders. However, while possible, it is less likely that fiber treatment alone would eliminate  
271 overabundance of opportunistic pathogens, for example, considering that opportunistic  
272 pathogens are a dense isolated cluster with no connection to fiber-degrading species.

273  
274 Profiling the patients' metagenome and comparing them to the reference dataset will show  
275 where they fall in the spectrum of dysbiosis. This concept, and the proposed method, holds true  
276 regardless of feature, disease, or dataset. However, the relative abundances of the features and  
277 therefore the range and thresholds for defining dysbiosis may differ across populations. Hence,  
278 it is important that the reference dataset is from the same source population as patients. Here,  
279 we used a cohort of neurologically healthy older adults from Birmingham, Alabama in United  
280 States for our reference dataset, as our patients are also from Birmingham. There are regional  
281 variation in microbiome, reflecting cultural, dietary, socioeconomic, and geographic influences.  
282 Despite regional variations, the main PD-associated features are robust and reproducible<sup>9-11,32</sup>.  
283 Even so, the relative abundances, and hence the thresholds for defining dysbiosis, may still vary  
284 across populations. Not every investigator can amass hundreds of controls to investigate  
285 population-specific abundances to set their thresholds. This impediment will be overcome soon  
286 by current efforts to collect all data generated and made public. These collaborative global  
287 efforts are aimed at meta-analyses, a by-product of which will be open-access to well-curated  
288 datasets from across the world that can be used as reference datasets to generate population-  
289 specific thresholds for biomarkers and companion diagnostics.

290

291 **Data availability**

292 The datasets used for biomarker development are openly public with no restrictions  
293 [<https://www.nature.com/articles/s41467-022-34667-x>]. The raw metagenomic sequences and  
294 accompanying metadata are at the NCBI SRA under BioProject ID PRJNA834801  
295 [<https://www.ncbi.nlm.nih.gov/bioproject/834801>], and post-QC and post taxonomic profiling  
296 data are on Zenodo [<https://zenodo.org/record/7246185>].

297

## 298 **Acknowledgements**

299 This work was supported by The Strain Endowed Chair in Parkinson's Disease to the University  
300 of Alabama at Birmingham (HP) and Aligning Science Across Parkinson's [ASAP-020527]  
301 through the Michael J. Fox Foundation for Parkinson's Research (MJFF) (HP, TRS, CFM). For  
302 the purpose of open access, the authors have applied a CC BY public copyright license to all  
303 Author Accepted Manuscripts arising from this submission. Opinions, interpretations,  
304 conclusions, and recommendations are those of the authors and are not necessarily endorsed  
305 by the funding agencies.

306

## 307 **Author contribution**

308 This is a collaborative team (genomics (HP), microbiology (TRS), statistics (CFM)). The  
309 lead/corresponding author (HP) conceptualized and developed the method. HP drafted the  
310 manuscript and all authors contributed to revision and approved the final version.

311

## 312 **Competing interest**

313 HP has intellectual property pending on Personalized Microbiome-Based Therapies, Serial No.:  
314 63/571,787; Filing Date: March 29, 2024. TRS is a co-inventor on intellectual property related  
315 to a small molecule microbiome-based therapy - US Patent 11,707,493 and 11,147, 792.

316

## 317 **References**

318

- 319 1 Collaborators, G. B. D. P. s. D. Global, regional, and national burden of Parkinson's  
320 disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.  
321 *Lancet Neurol* **17**, 939-953 (2018). [https://doi.org/10.1016/S1474-4422\(18\)30295-3](https://doi.org/10.1016/S1474-4422(18)30295-3)
- 322 2 Obeso, J. A. *et al.* Past, present, and future of Parkinson's disease: A special essay on  
323 the 200th Anniversary of the Shaking Palsy. *Mov Disord* **32**, 1264-1310 (2017).  
324 <https://doi.org/10.1002/mds.27115>

- 325 3 Braak, H., Rub, U., Gai, W. P. & Del Tredici, K. Idiopathic Parkinson's disease: possible  
326 routes by which vulnerable neuronal types may be subject to neuroinvasion by an  
327 unknown pathogen. *J Neural Transm (Vienna)* **110**, 517-536 (2003).  
328 <https://doi.org/10.1007/s00702-002-0808-2>
- 329 4 Horsager, J. *et al.* Brain-first versus body-first Parkinson's disease: a multimodal imaging  
330 case-control study. *Brain* **143**, 3077-3088 (2020). <https://doi.org/10.1093/brain/awaa238>
- 331 5 Holmqvist, S. *et al.* Direct evidence of Parkinson pathology spread from the  
332 gastrointestinal tract to the brain in rats. *Acta Neuropathol* **128**, 805-820 (2014).  
333 <https://doi.org/10.1007/s00401-014-1343-6>
- 334 6 Breen, D. P., Halliday, G. M. & Lang, A. E. Gut-brain axis and the spread of alpha-  
335 synuclein pathology: Vagal highway or dead end? *Mov Disord* **34**, 307-316 (2019).  
336 <https://doi.org/10.1002/mds.27556>
- 337 7 Kim, S. *et al.* Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to  
338 the Brain Models Parkinson's Disease. *Neuron* **103**, 627-641 e627 (2019).  
339 <https://doi.org/10.1016/j.neuron.2019.05.035>
- 340 8 Fan, Y. & Pedersen, O. Gut microbiota in human metabolic health and disease. *Nat Rev*  
341 *Microbiol* **19**, 55-71 (2021). <https://doi.org/10.1038/s41579-020-0433-9>
- 342 9 Wallen, Z. D. *et al.* Metagenomics of Parkinson's disease implicates the gut microbiome  
343 in multiple disease mechanisms. *Nat Commun* **13**, 6958 (2022).  
344 <https://doi.org/10.1038/s41467-022-34667-x>
- 345 10 Romano, S. *et al.* Meta-analysis of the Parkinson's disease gut microbiome suggests  
346 alterations linked to intestinal inflammation. *NPJ Parkinsons Dis* **7**, 27 (2021).  
347 <https://doi.org/10.1038/s41531-021-00156-z>
- 348 11 Toh, T. S. *et al.* Gut microbiome in Parkinson's disease: New insights from meta-  
349 analysis. *Parkinsonism Relat Disord* **94**, 1-9 (2022).  
350 <https://doi.org/10.1016/j.parkreldis.2021.11.017>
- 351 12 Chen, S. G. *et al.* Exposure to the Functional Bacterial Amyloid Protein Curli Enhances  
352 Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and *Caenorhabditis elegans*. *Sci*  
353 *Rep* **6**, 34477 (2016). <https://doi.org/10.1038/srep34477>
- 354 13 Sampson, T. R. *et al.* A gut bacterial amyloid promotes alpha-synuclein aggregation and  
355 motor impairment in mice. *Elife* **9** (2020). <https://doi.org/10.7554/eLife.53111>
- 356 14 Sampson, T. R. *et al.* Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a  
357 Model of Parkinson's Disease. *Cell* **167**, 1469-1480 e1412 (2016).  
358 <https://doi.org/10.1016/j.cell.2016.11.018>

- 359 15 Matheoud, D. *et al.* Intestinal infection triggers Parkinson's disease-like symptoms in  
360 Pink1(-/-) mice. *Nature* **571**, 565-569 (2019). <https://doi.org/10.1038/s41586-019-1405-y>
- 361 16 Radisavljevic, N. *et al.* Effects of Gut Microbiota Alterations on Motor, Gastrointestinal,  
362 and Behavioral Phenotype in a Mouse Model of Parkinson's Disease. *J Parkinsons Dis*  
363 **12**, 1479-1495 (2022). <https://doi.org/10.3233/JPD-223165>
- 364 17 Bhattarai, Y. *et al.* Role of gut microbiota in regulating gastrointestinal dysfunction and  
365 motor symptoms in a mouse model of Parkinson's disease. *Gut Microbes* **13**, 1866974  
366 (2021). <https://doi.org/10.1080/19490976.2020.1866974>
- 367 18 Sun, M. F. *et al.* Neuroprotective effects of fecal microbiota transplantation on MPTP-  
368 induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-alpha  
369 signaling pathway. *Brain Behav Immun* **70**, 48-60 (2018).  
370 <https://doi.org/10.1016/j.bbi.2018.02.005>
- 371 19 Zhao, Z. *et al.* Fecal microbiota transplantation protects rotenone-induced Parkinson's  
372 disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4  
373 signaling pathway through the microbiota-gut-brain axis. *Microbiome* **9**, 226 (2021).  
374 <https://doi.org/10.1186/s40168-021-01107-9>
- 375 20 Bisht, R., Kaur, B., Gupta, H. & Prakash, A. Ceftriaxone mediated rescue of nigral  
376 oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats.  
377 *Neurotoxicology* **44**, 71-79 (2014). <https://doi.org/10.1016/j.neuro.2014.05.009>
- 378 21 Du, Y. *et al.* Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the  
379 MPTP model of Parkinson's disease. *Proc Natl Acad Sci U S A* **98**, 14669-14674 (2001).  
380 <https://doi.org/10.1073/pnas.251341998>
- 381 22 Pu, Y. *et al.* Antibiotic-induced microbiome depletion protects against MPTP-induced  
382 dopaminergic neurotoxicity in the brain. *Aging (Albany NY)* **11**, 6915-6929 (2019).  
383 <https://doi.org/10.18632/aging.102221>
- 384 23 Kaur, B. & Prakash, A. Ceftriaxone attenuates glutamate-mediated neuro-inflammation  
385 and restores BDNF in MPTP model of Parkinson's disease in rats. *Pathophysiology* **24**,  
386 71-79 (2017). <https://doi.org/10.1016/j.pathophys.2017.02.001>
- 387 24 Abdel-Haq, R. *et al.* A prebiotic diet modulates microglial states and motor deficits in  
388 alpha-synuclein overexpressing mice. *Elife* **11** (2022).  
389 <https://doi.org/10.7554/eLife.81453>
- 390 25 Sorbara, M. T. & Pamer, E. G. Microbiome-based therapeutics. *Nat Rev Microbiol* **20**,  
391 365-380 (2022). <https://doi.org/10.1038/s41579-021-00667-9>

- 392 26 Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome-gut-brain axis in Parkinson disease -  
393 from basic research to the clinic. *Nat Rev Neurol* **18**, 476-495 (2022).  
394 <https://doi.org/10.1038/s41582-022-00681-2>
- 395 27 Hall, D. A. *et al.* An open label, non-randomized study assessing a prebiotic fiber  
396 intervention in a small cohort of Parkinson's disease participants. *Nat Commun* **14**, 926  
397 (2023). <https://doi.org/10.1038/s41467-023-36497-x>
- 398 28 DuPont, H. L. *et al.* Fecal microbiota transplantation in Parkinson's disease-A  
399 randomized repeat-dose, placebo-controlled clinical pilot study. *Front Neurol* **14**,  
400 1104759 (2023). <https://doi.org/10.3389/fneur.2023.1104759>
- 401 29 Cheng, Y. *et al.* Efficacy of fecal microbiota transplantation in patients with Parkinson's  
402 disease: clinical trial results from a randomized, placebo-controlled design. *Gut Microbes*  
403 **15**, 2284247 (2023). <https://doi.org/10.1080/19490976.2023.2284247>
- 404 30 Segal, A., Zlotnik, Y., Moyal-Atias, K., Abuhasira, R. & Ifergane, G. Fecal microbiota  
405 transplant as a potential treatment for Parkinson's disease - A case series. *Clin Neurol*  
406 *Neurosurg* **207**, 106791 (2021). <https://doi.org/10.1016/j.clineuro.2021.106791>
- 407 31 Xue, L. J. *et al.* Fecal microbiota transplantation therapy for Parkinson's disease: A  
408 preliminary study. *Medicine (Baltimore)* **99**, e22035 (2020).  
409 <https://doi.org/10.1097/MD.00000000000022035>
- 410 32 Wallen, Z. D. *et al.* Characterizing dysbiosis of gut microbiome in PD: evidence for  
411 overabundance of opportunistic pathogens. *NPJ Parkinsons Dis* **6**, 11 (2020).  
412 <https://doi.org/10.1038/s41531-020-0112-6>  
413

**Table 1. Six main dysbiotic features of PD gut microbiome**

Feature	Species composition of feature	PD association	Number of connections
Opp pathogens	<i>Actinomyces turicensis</i>	Increased as cluster	8
Opp pathogens	<i>Anaerococcus octavius</i>	Increased as cluster	4
Opp pathogens	<i>Anaerococcus vaginalis</i>	Increased as cluster	5
Opp pathogens	<i>Atopobium minutum</i>	Increased as cluster	8
Opp pathogens	<i>Corynebacterium amycolatum</i>	Increased as cluster	2
Opp pathogens	<i>Corynebacterium aurimucosum</i>	Increased as cluster	2
Opp pathogens	<i>Finnegoldia magna</i>	Increased as cluster	7
Opp pathogens	<i>Gemella asaccharolytica</i>	Increased as cluster	2
Opp pathogens	<i>Peptoniphilus harei</i>	Increased as cluster	1
Opp pathogens	<i>Peptoniphilus lacrimalis</i>	Increased as cluster	3
Opp pathogens	<i>Peptoniphilus sp HMSC062D09</i>	Increased as cluster	7
Opp pathogens	<i>Porphyromonas asaccharolytica</i>	Increased	6
Opp pathogens	<i>Porphyromonas sp HMSC065F10</i>	Increased as cluster	11
Opp pathogens	<i>Porphyromonas uenonis</i>	Increased as cluster	6
Opp pathogens	<i>Prevotella bergensis</i>	Increased as cluster	1
Opp pathogens	<i>Prevotella buccalis</i>	Increased as cluster	10
Opp pathogens	<i>Prevotella disiens</i>	Increased as cluster	1
Opp pathogens	<i>Prevotella timonensis</i>	Increased as cluster	8
Opp pathogens	<i>Varibaculum cambriense</i>	Increased as cluster	10
<i>Bifidobacteria</i>	<i>Bifidobacterium dentium</i>	Increased	12
<i>Bifidobacteria</i>	<i>Bifidobacterium bifidum</i>	Increased	3
<i>Bifidobacteria</i>	<i>Bifidobacterium breve</i>	Increased	24
<i>Bifidobacteria</i>	<i>Bifidobacterium gallinarum</i>	Increased	14
<i>Bifidobacteria</i>	<i>Bifidobacterium longum</i>	Increased	5
<i>Bifidobacteria</i>	<i>Bifidobacterium pullorum</i>	Increased	12
<i>Bifidobacteria</i>	<i>Bifidobacterium saeculare</i>	Increased	13
<i>Lactobacillus</i>	<i>Lactobacillus fermentum</i>	Increased	14
<i>Lactobacillus</i>	<i>Lactobacillus gasseri</i>	Increased	10
<i>Lactobacillus</i>	<i>Lactobacillus paragasseri</i>	Increased	9
<i>Lactobacillus</i>	<i>Lactobacillus salivarius</i>	Increased	9
<i>Lactobacillus</i>	<i>Lactobacillus reuteri</i>	Increased	1
<i>Lactobacillus</i>	<i>Lactobacillus rhamnosus</i>	Increased	11
<i>Strepto / Actino</i>	<i>Actinomyces naeslundii</i>	Increased	4
<i>Strepto / Actino</i>	<i>Actinomyces oris</i>	Increased	16
<i>Strepto / Actino</i>	<i>Actinomyces sp HPA0247</i>	Increased	3
<i>Strepto / Actino</i>	<i>Actinomyces sp oral taxon 448</i>	Increased	3
<i>Strepto / Actino</i>	<i>Streptococcus anginosus group</i>	Increased	10

<i>Strepto / Actino</i>	<i>Streptococcus mutans</i>	Increased	13
<i>Strepto / Actino</i>	<i>Streptococcus vestibularis</i>	Increased	15
<i>Strepto / Actino</i>	<i>Streptococcus lutetiensis</i>	Increased	3
<i>E. coli / klebsiella</i>	<i>Escherichia coli</i>	Increased	5
<i>E. coli / klebsiella</i>	<i>Klebsiella pneumoniae</i>	Increased	3
<i>E. coli / klebsiella</i>	<i>Klebsiella quasipneumoniae</i>	Increased	3
Fiber-degraders	<i>Blautia wexlerae</i>	Decreased	17
Fiber-degraders	<i>Blautia hansenii</i>	Decreased	17
Fiber-degraders	<i>Anaerostipes hadrus</i>	Decreased	48
Fiber-degraders	<i>Clostridium sp CAG 58</i>	Decreased	27
Fiber-degraders	<i>Eubacterium eligens</i>	Decreased	47
Fiber-degraders	<i>Eubacterium hallii</i>	Decreased	52
Fiber-degraders	<i>Eubacterium ramulus</i>	Decreased	25
Fiber-degraders	<i>Eubacterium rectale</i>	Decreased	21
Fiber-degraders	<i>Eubacterium sp CAG 38</i>	Decreased	22
Fiber-degraders	<i>Faecalibacterium prausnitzii</i>	Decreased	59
Fiber-degraders	<i>Fusicatenibacter saccharivorans</i>	Decreased	45
Fiber-degraders	<i>Roseburia faecis</i>	Decreased	21
Fiber-degraders	<i>Roseburia intestinalis</i>	Decreased	21
Fiber-degraders	<i>Roseburia inulinivorans</i>	Decreased	27
Fiber-degraders	<i>Ruminococcus bicirculans</i>	Decreased	33
Fiber-degraders	<i>Ruminococcus lactaris</i>	Decreased	12

We selected species that individually, or as a cluster, were significantly elevated or reduced in PD<sup>9</sup>, and assigned them to a “feature” according to the correlation in their abundances (connectivity, see **Figure 2**) and their taxonomic relatedness (members of same genus). Here, our aim was to demonstrate the method, for which we strived for a balance between capturing the most robust association with PD and reducing the complexity. Features can be redefined to accommodate the aims of the investigation.

**Table 2. Defining dysbiotic**

Feature	Relative abundance of feature in 234 NHC			Relative abundance of feature in 490 PD			N PD outside 95% CI of NHC
	Mean	Upper 95% CI	Lower 95% CI	Mean	Upper 95% CI	Lower 95% CI	
Opp. pathogens	0.01%	<b>0.01%</b>	0.00%	0.10%	0.20%	0.00%	66
<i>Bifidobacteria</i>	2.06%	<b>2.66%</b>	1.47%	5.07%	5.98%	4.17%	161
<i>Lactobacillus</i>	0.11%	<b>0.19%</b>	0.04%	0.55%	0.74%	0.36%	103
<i>Streptococcus / Actinomyces</i>	0.19%	<b>0.33%</b>	0.06%	0.39%	0.54%	0.25%	94
<i>E. coli / Klebsiella</i>	1.47%	<b>2.23%</b>	0.72%	1.94%	2.44%	1.43%	86
Fiber-degraders	22.35%	23.88%	<b>20.81%</b>	15.29%	16.36%	14.22%	333


Each feature is composed of several species, as shown in **Table 1**. The relative abundance of each species in each individual was calculated as reported before<sup>9</sup> and can be found here <https://zenodo.org/record/7246185>. We calculated relative abundance of each feature in each neurologically healthy control (NHC) and individual with PD by summing the relative abundances of the species within the feature for that individual. We then calculated the mean and 95% confidence interval (CI) of the mean in the NHC and PD separately. We set the threshold for defining dysbiotic at the upper 95% CI of NHC for features that are elevated in PD, and at lower 95% CI of NHC for fiber-degraders that are reduced in PD. Last column is the number of PD patients, among 490 total, who were called dysbiotic for each feature. For example, in 161 of 490 PD patients, the relative abundance of *Bifidobacteria* was higher than 2.66% which was the upper 95% CI limit of NHC. Similarly, in 333 of 490 patients, the relative abundance of fiber-degrading bacteria was lower than 20.81% which was the lower 95% CI limit in NHC.





### **Figure 1. The method.**

The concept is to develop a biomarker tool that will help us “see” if a person’s microbiome is dysbiotic, and if so, what are their dysbiotic features. The goal is to optimize patient selection for clinical trials of microbiome-based studies, and upon approval, use it as diagnostic companion for personalized treatment. A reference dataset is built by obtaining the metagenomic profiles of a non-disease cohort that represents the same population as the persons to be studied or treated. Once this infrastructure is in place, one can pick any feature (from a microbial gene to species to polymicrobial clusters), calculate its relative abundance and confidence interval (CI) in the non-disease group, and set thresholds for defining dysbiotic and non-dysbiotic. Application entails obtaining the metagenomic profile of the individual of interest and comparing it to the non-disease population. Here, we selected 6 PD-associated features (each a polymicrobial cluster), 5 of which are elevated in PD, and one reduced in PD<sup>9</sup>. We set the threshold at 95%CI of the non-disease reference dataset. A person would be marked as dysbiotic for a feature if their relative abundance of that feature is above (for features that are elevated in PD) or below (for feature that are reduced) the 95%CI in non-disease population.



## Figure 2. Fireworks

Polymicrobial clusters of species in PD gut microbiome. Pairwise correlation in relative abundances of all species detected in 490 unique PD gut metagenomes (i.e. 490 individuals with PD) was calculated and plotted (methods are described in Wallen et al <sup>9</sup>). Each circle (node) represents one species and the curved lines (edges) connect species whose relative abundance correlate with each other (at correlation  $|r| > 0.2$ , permuted  $P < 0.05$ ). Here, we have highlighted PD-associated species that were selected for this study, denoting by color the 6 dysbiotic features (species within each feature are listed in **Table 1**):

Blue: Opportunistic pathogens (elevated in PD)

Red: fiber-degraders (reduced in PD)

Yellow: *E. coli* and *Klebsiella* (elevated in PD)


Green: *Bifidobacteria* (elevated in PD)

Orange: *Lactobacillus* (elevated in PD)

Purple: *Streptococcus* and *Actinomyces* (elevated in PD)


Grey: associated with PD, not selected as feature

Empty circle: not associated with PD



b

	Opp path	<i>Bifido-bacteria</i>	<i>Lacto-bacillus</i>	<i>Strepto /Actino</i>	<i>E. coli / Klebsiella</i>	Fiber-degraders
Opp Pathogens	66					
<i>Bifidobacteria</i>	33	161				
<i>Lactobacillus</i>	15	49	103			
<i>Strepto / Actino</i>	18	50	47	94		
<i>E. coli / Klebsiella</i>	13	27	27	22	86	
Fiber-Degraders	57	135	88	81	69	333
No Others	5	18	5	5	9	96



### Figure 3. Subtyping PD by the dysbiotic features of the gut microbiome.

The total number of patients is 490. The total number of patients with a dysbiotic feature is 392 (=490-98). The number of patients with a given dysbiotic feature are given in a-c. Actual numbers are given so that percentages can be calculated with the desired denominator.

(a) Proportion of PD patients with different dysbiotic features.

- Elevated features: number of PD persons, among the 490, who had an abundance higher than upper limit of the 95% CI of the abundance in neurologically healthy control (NHC).
- Reduced feature: number of PD persons, among the 490, who had an abundance lower than the lower limit of 95% CI of the abundance in NHC.
- No detectable dysbiosis: 98 of 490 (20%) did not fall outside 95% CI of NHC for any feature. 76 of 490 (16%) of PD persons fit the more cautious definition of non-dysbiotic, whose abundances for every elevated feature (opportunistic pathogens, *Bifidobacteria*, *Lactobacillus*, *Streptococcus* and *Actinomyces* (Strepto/Actino), and *E. coli/Klebsiella*) was below the NHC mean, and their abundance for reduced fiber-degrading bacteria was above the NHC mean.

(b) Pairwise overlap in features, n=number of patients, from 490, who have the two specified features. The total for six features (the diagonal) is 843, nearly double the number of 490 subjects, because features do co-occur in an individual. For example, 66 of 490 subjects had elevated (>95%CI of NHC) levels of opportunistic pathogens, among them, 33 (50%) also had elevated *Bifidobacteria*. Or the example in the text, 71% (=333-96)/333) of low fiber-degraders had high level of at least one other feature.

(c) Overlap across the 5 features that are elevated in PD (fiber-reducers not included for legibility). For example, 19 subjects have elevated levels (>95%CI of NHC) of *Streptococcus* and *Actinomyces* only, another 2 subjects have high *Streptococcus* and *Actinomyces* and high opportunistic pathogens, another 3 have high *Streptococcus* and *Actinomyces*, high opportunistic pathogens, and high *Lactobacillus*, etc.